(via NewsDirect)
Gouldstone discusses the significant changes made to the company's strategy following his appointment in August, saying that his primary focus has been on maximising the commercial and scientific value of the company's Immune Insights platform, centred in their
The new strategy, announced on
Since taking the helm, he has conducted a comprehensive review of the business, covering everything from finances to operations. The outcome has been positive, with a productive team in
Gouldstone's short tenure has already seen tangible successes, including the signing of four deals aligned with the new strategy, indicating early commercial traction. He anticipates continued growth and success in line with the company's evolving strategy and robust pipeline.
Contact Details
+44 20 7989 0813
uk@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source